MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer

This article was originally published here

“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part of our strategy to advance margetuximab

The post MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply